Euro
USD
British Pound
NULL
Product Description
Skp2 p45 (P399) polyclonal Antibody | BS1325 | Bioworld
Host: Rabbit
Reactivity: Human
Application: WB IHC IF
Application Range: WB: 1:500~1:1000 IHC: 1:50~1:200 IF: 1:50~1:200
Background: The critical role that the family of regulatory proteins known as cyclins plays in eukaryotic cell cycle regulation is well established. The best characterized cyclin complex is the mitotic cyclin B/Cdc2 p34 kinase, the active component of MPF (maturation promoting factor) . Cyclin A accumulates prior to cyclin B in the cell cycle, appears to be involved in control of S phase and has been shown to associate with cyclin dependent kinase 2 (Cdk2) . In addition, cyclin A has been implicated in cell transformation and is found in complexes with E1A, transcription factors DP-1 and E2F, and retinoblastoma protein p110. Two cyclin A-Cdk2 complex binding proteins, Skp1 p19 and Skp2 p45, have been described. Although the Skps (S phase kinase-associated proteins) associate with the active cyclin A-Cdk2 complex, they do not exhibit any regulatory effects on the complex. Abolition of Skp2 p45 function by either microinjection of anti-p45 antibodies or addition of antisense oligonucleotides prevents entry into S phase of both normal and transformed cells.
Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Specificity: SKP2 p45 (P399) polyclonal Antibody detects endogenous levels of SKP2 p45 protein.
Molecular Weight: ~ 55 kDa
Note: For research use only, not for use in diagnostic procedure.
Alternative Names: S-phase kinase-associated protein 2; Cyclin-A/CDK2-associated protein p45; F-box protein Skp2; F-box/LRR-repeat protein 1; p45skp2; SKP2; FBXL1
Immunogen: Synthetic peptide, corresponding to amino acids 369-419 of Human Skp2 p45.
Conjugate: Unconjugated
Modification: Unmodification
Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .
Pathway:
